Analysts expect La Jolla Pharmaceutical (NASDAQ:LJPC) to announce ($1.04) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.02) and the lowest is ($1.07). La Jolla Pharmaceutical posted earnings of ($1.73) per share in the same quarter last year, which suggests a positive year over year growth rate of 39.9%. The firm is expected to issue its next earnings report on Monday, March 2nd.
According to Zacks, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.43) per share for the current year, with EPS estimates ranging from ($4.50) to ($4.39). For the next financial year, analysts expect that the company will report earnings of ($3.03) per share, with EPS estimates ranging from ($3.46) to ($2.49). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative return on equity of 715.11% and a negative net margin of 683.88%. The company had revenue of $5.71 million during the quarter, compared to analysts’ expectations of $6.96 million.
Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its holdings in shares of La Jolla Pharmaceutical by 2.9% in the 3rd quarter. State Street Corp now owns 427,553 shares of the biopharmaceutical company’s stock valued at $3,762,000 after acquiring an additional 11,890 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of La Jolla Pharmaceutical by 394.8% during the third quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock worth $3,309,000 after purchasing an additional 299,995 shares during the last quarter. Trellus Management Company LLC lifted its position in La Jolla Pharmaceutical by 127.1% during the third quarter. Trellus Management Company LLC now owns 26,845 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 15,024 shares during the period. Boxer Capital LLC acquired a new position in La Jolla Pharmaceutical during the second quarter valued at $5,319,000. Finally, Morgan Stanley boosted its holdings in La Jolla Pharmaceutical by 0.7% in the second quarter. Morgan Stanley now owns 420,862 shares of the biopharmaceutical company’s stock valued at $3,893,000 after purchasing an additional 2,780 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.
Shares of LJPC traded up $0.02 during trading hours on Friday, reaching $3.23. 925,777 shares of the company traded hands, compared to its average volume of 860,915. The stock has a market capitalization of $87.58 million, a P/E ratio of -0.41 and a beta of 1.84. La Jolla Pharmaceutical has a 12-month low of $2.30 and a 12-month high of $14.87. The business has a fifty day moving average price of $5.50 and a 200-day moving average price of $8.15.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.